SolasCure conducted a Phase IIa clinical trial, with results published in the International Wound Journal, for their Aurase Wound Gel product being used on venous leg ulcer patients across the US, UK and Hungary. The trial not only demonstrated effiacy, but also a strong safety profile and did not add to patients' existing pain burden. Results such as these will enable SolasCure to receive investment to conduct further trials as they bring the product to market. Read more here.